Mednet Logo
HomeNeurologyQuestion

Do you consider bleeding risk in elderly, frail patients with atrial fibrillation to be similar for all NOACs?

1
4 Answers
Mednet Member
Mednet Member
Cardiology · Weill Cornell Medical College of Cornell University

I believe that apixaban carries a lower risk of bleeding, with particular reference to GI bleed, when compared to rivaroxaban and dabigatran. This is true in the population of AF patients at large and most probably in frail patients as well.

Register or Sign In to see full answer

Mednet Member
Mednet Member
Cardiology · Yale New Haven Hospital Heart And Vascular Center

The prior evidence would suggest that not all NOACS have the same bleeding risk. More specifically, Apixaban appears to have a lower risk of GI bleeding than Rivaroxaban. While this is based on observational analyses, and head-to-head trials of non-generic medications are hard to come by, I have enc...

Register or Sign In to see full answer

Mednet Member
Mednet Member
Neurology · University of Colorado, Climate & Health Dept

From lowest to highest risk of intracranial and extracranial bleeding based on anecdotal experience:

apixaban < rivaroxaban < dabigatran < warfarin

I've never seen a patient on edoxaban.

Register or Sign In to see full answer

Mednet Member
Mednet Member
Cardiology · The George Washington University Hospital

Apixiban, administered q 12 H, has the shortest half life, and would dissipate most rapidly if bleeding were to occur.

Register or Sign In to see full answer

Do you consider bleeding risk in elderly, frail patients with atrial fibrillation to be similar for all NOACs? | Mednet